Literature DB >> 24024006

A comparison of epidural infusion of 0.2, 0.25, and 0.3% ropivacaine with fentanyl after unilateral total knee arthroplasty.

Jae Ho Lee1, Nam Oh Kim, Eun Kyoung Ahn.   

Abstract

Entities:  

Year:  2013        PMID： 24024006      PMCID： PMC3766789          DOI： 10.4097/kjae.2013.65.2.180

Source DB:  PubMed          Journal:  Korean J Anesthesiol        ISSN： 2005-6419


× No keyword cloud information.
  5 in total

1.  Continuous epidural ropivacaine 0.2% for analgesia after lower abdominal surgery.

Authors:  R C Etches; W D Writer; D Ansley; P A Nydahl; B Y Ong; A Lui; N Badner; S Kawolski; H Muir; R Shukla; W S Beattie
Journal:  Anesth Analg       Date:  1997-04       Impact factor: 5.108

2.  Continuous epidural infusion of ropivacaine for the prevention of postoperative pain after major orthopaedic surgery: a dose-finding study.

Authors:  N H Badner; D Reid; P Sullivan; S Ganapathy; E T Crosby; J McKenna; A Lui
Journal:  Can J Anaesth       Date:  1996-01       Impact factor: 5.063

3.  Comparative systemic toxicity of convulsant and supraconvulsant doses of intravenous ropivacaine, bupivacaine, and lidocaine in the conscious dog.

Authors:  H S Feldman; G R Arthur; B G Covino
Journal:  Anesth Analg       Date:  1989-12       Impact factor: 5.108

4.  Cardiac electrophysiologic properties of bupivacaine and lidocaine compared with those of ropivacaine, a new amide local anesthetic.

Authors:  R Moller; B G Covino
Journal:  Anesthesiology       Date:  1990-02       Impact factor: 7.892

5.  Epidural ropivacaine infusion for postoperative analgesia after major lower abdominal surgery--a dose finding study.

Authors:  D A Scott; D M Chamley; P H Mooney; R K Deam; A H Mark; B Hägglöf
Journal:  Anesth Analg       Date:  1995-11       Impact factor: 5.108
  5 in total
  1 in total

1.  Preparation of novel biodegradable ropivacaine microspheres and evaluation of their efficacy in sciatic nerve block in mice.

Authors:  Qiang Ni; Wurong Chen; Lei Tong; Jue Cao; Chao Ji
Journal:  Drug Des Devel Ther       Date:  2016-08-04       Impact factor: 4.162
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.